Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Veracyte ( (VCYT) ) just unveiled an update.
On March 16, 2026, Veracyte, Inc. announced it had appointed former Myriad Genetics executive Dr. Kevin Haas as Chief Development and Technology Officer, effective March 24, 2026, bringing extensive experience in technology, engineering and bioinformatics leadership to its executive team. The move signals Veracyte’s efforts to strengthen its technological and product-development capabilities as it competes in the precision diagnostics market.
Under an offer letter signed on March 13, 2026, Dr. Haas will receive a $500,000 base salary, be eligible for an annual cash bonus targeted at 55% of earnings, and be granted time-based and performance-based restricted stock units valued at $1.5 million each, subject to multi-year vesting and performance goals. Veracyte will also provide its standard executive indemnification, and confirmed there are no related-party or conflict-of-interest relationships tied to his appointment, underscoring standard governance practices.
The most recent analyst rating on (VCYT) stock is a Hold with a $35.00 price target. To see the full list of analyst forecasts on Veracyte stock, see the VCYT Stock Forecast page.
Spark’s Take on VCYT Stock
According to Spark, TipRanks’ AI Analyst, VCYT is a Neutral.
The score is driven primarily by improved fundamentals (profitability and accelerating free cash flow with a low-leverage balance sheet). Offsetting this are weak technical momentum (below key moving averages with negative MACD) and a demanding valuation (high P/E). Earnings-call guidance and sentiment are constructive but include margin-step-down and reimbursement/timing risks for new launches.
To see Spark’s full report on VCYT stock, click here.
More about Veracyte
Veracyte, Inc. is a diagnostics company operating in the precision medicine and genomic testing industry, developing and commercializing tests that aim to improve the diagnosis and treatment of disease. The company focuses on leveraging advanced molecular and bioinformatics technologies to deliver clinically actionable insights for physicians and patients across multiple disease areas.
Average Trading Volume: 827,036
Technical Sentiment Signal: Sell
Current Market Cap: $2.55B
For a thorough assessment of VCYT stock, go to TipRanks’ Stock Analysis page.